In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2022

Annual industry ranking and forecast

Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review

Novartis Unit’s Strategy Remains Unaltered As Parent Company Explores All Options

Executive Summary

Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.

You may also be interested in...



$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options

Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.

‘Challenging’ Times For Sandoz As COVID Bites

Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.

Sandoz Aims To Be ‘First In And Last Out’ In North America

Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV124934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel